FINWIRES · TerminalLIVE
FINWIRES

GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint

By

GSK (GSK) licensor Hansoh's phase 3 trial of risvutatug rezetecan in osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.

The trial, which was conducted in China in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, showed that the therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy, according to the statement.

Hansoh also reported consistent benefit across secondary endpoints like overall survival, GSK added.

Safety profile was consistent with previous findings in the same tumor type, with no new safety signals identified, the company said. Hansoh will use the trial data for regulatory submissions in China, GSK said.

Price: $53.96, Change: $+1.98, Percent Change: +3.80%

Related Articles

Wire

AuMEGA Metals Starts Inaugural Diamond Drilling at Canada Targets; Shares Fall 9%

AuMEGA Metals (ASX:AAM) started inaugural diamond drilling at targets at Isle aux Morts Granite and and the adjoining Cape Ray West area along the Cape Ray shear zone in Canada, according to a Tuesday Australian bourse filing.The drilling program is designed to test a series of structural, geochemical, and geophysical targets defined by integrating geological mapping, surface geochemistry, geophysics, and structural interpretation, per the filing.The company's shares fell nearly 9% in recent trading on Tuesday.

ASX:AAM
Wire

Brown & Brown Q2 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q2 adjusted earnings late Monday of $1.07 per diluted share, up from $1.03 a year earlier.Analysts polled by FactSet expected $1.08.Revenue in the three months ended June 30 rose to $1.68 billion from $1.29 billion a year earlier.Analysts expected $1.71 billion.The company's shares fell 1.8% in after-hours trading.

$BRO
Wire

Celestica Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Celestica (CLS) reported Q2 adjusted earnings late Monday of $2.54 per diluted share, up from $1.39 a year earlier.Analysts polled by FactSet expected $2.27.Revenue in the three months ended June 30 rose to $4.7 billion from $2.89 billion a year earlier.Analysts expected $4.33 billion.Celestica expects Q3 adjusted EPS of $2.88 to $3.08 on revenue of $5.25 to $5.55 billion.Analysts project EPS of $2.65 on revenue of $4.94 billion.The company boosted full-year guidance to adjusted EPS of $11.30 on revenue of $20.5 billion from the prior forecast of EPS of $10.15 on revenue of $19 billion.Analysts project EPS of $10.13 on revenue of $18.95 billion.Celestica shares rose 9.4% in after-hours trading.

$CLS